Genzyme Surgical Products
This article was originally published in The Gray Sheet
Executive Summary
Cardiovascular and general surgical biomaterials business receives 510(k) clearance to market the Sepramesh hyaluron-based biosurgical composite for hernia repairs, the company announces March 22. Sepramesh contains a bioresorbable barrier to prevent adhesions common among traditional mesh products. Genzyme plans a roll-out in the second quarter of 2000 targeting the estimated $25 mil. market opportunity among the 64,000 annual U.S. incisional hernia repair procedures
You may also be interested in...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.